Physician profile
Paul Andrew Glazer
NPI 1750321287
$2,090,555.90
in general payments reported to CMS, 2019-2025
14 companies · $218K in 2025
The $218K reported for 2025 was more than what 96% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690K · 2020: $79K · 2021: $334K · 2022: $92K · 2023: $293K · 2024: $384K · 2025: $218K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $774K · Consulting Fee: $104K · Travel and Lodging: $14K · Food and Beverage: $3,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $773,833.58 |
| Consulting Fee | $104,161.67 |
| Travel and Lodging | $13,557.21 |
| Food and Beverage | $3,578.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $1,405,786.91 | 2019-2025 | Other - Miscellaneous, Solus Alif, Identiti |
| Nuvasive, INC. | $649,810.59 | 2019-2020 | |
| Globus Medical, INC. | $19,872.60 | 2019-2025 | A/R Femoral Nail, Creo 5.5, Excelsius3d Imaging System |
| Zimmer Biomet Holdings, INC. | $9,778.57 | 2019-2025 | |
| Orthofix Medical, INC. | $2,560.18 | 2025 | Lattus, 7d Surgical System, Mariner |
| Arthrex, INC. | $1,095.90 | 2025 | |
| Surgalign Spine Technologies, INC. | $619.01 | 2020-2022 | |
| Cerapedics INC. | $376.37 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $187.00 | 2019 | |
| Highridge Medical LLC | $180.40 | 2024 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Zimvie INC. | $148.07 | 2023 | |
| Nuvasive Specialized Orthopedics, INC. | $88.80 | 2019 | |
| Smith+Nephew, INC. | $30.15 | 2022 | |
| Seaspine Orthopedics Corporation | $21.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Glazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.